Business Context and Reporting Period
This Form 6-K filing by BioBlast Pharma Ltd. (also referenced as Enlivex Ltd. in metadata) covers the month of June 2016, with the report dated June 23, 2016. The registrant is a foreign private issuer based in Tel Aviv, Israel.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is a current event disclosure and does not contain financial statements.
Material Changes
The primary material change disclosed is a corporate governance event:
- On June 20, 2016, the company received notice of the resignation of Mr. Isaac Krymolowski from his position as a director.
- The resignation was effective immediately.
- Mr. Krymolowski cited personal reasons for his departure.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for financial guidance, future outlook, management commentary on operations, specific risks, contingencies, or unusual items beyond the director resignation.
Key Facts for Investor Verification
- Verify the composition of the Board of Directors following the immediate resignation of Mr. Isaac Krymolowski.
- Confirm if the resignation impacts any ongoing corporate governance or strategic initiatives.
- Note that this filing contains no financial performance data for the period.